Effect of Enalaprilat on nitric oxide activity in coronary artery disease

American Journal of Cardiology

Volumn 84, Issue 1, 1999, Pages 1-6

  Prasad, Abhiram ^a   Husain, Syed ^a   Quyyumi, Arshed A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DILATATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; FEMORAL ARTERY FLOW; HEART PROTECTION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033024364     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00182-4     Document Type: Article

References (34)

1. Ross R. The pathogenesis of atherosclerosis a prospective for the 1990s . Nature. 362:1993;801-809.
2. Powell J.S., Clozel J.P., Muller R.K.M., Kuhn H., Hefti F., Hosang M., Baumgartner H.R. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 245:1989;186-188.
3. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol. 28:1996;803-812.
4. Bhoola K.D., Figueroa C.D., Worhty K. Bioregulation of kinins, kallikreins, kininogens, and kininases. Pharmacol Rev. 44:1992;1-80.
5. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 94:1996;2756-2767.
6. Rajagopalan S., Kurz S., Münzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 97:1996;1916-1923.
7. O'Kane K.P., Webb D.J., Collier J.G., Vallance P.J. Local L-NG-monomethyl -arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol. 38:1994;311-315.
8. Kerth P.A., Vanhoutte P.M. Effect of perindoprilat on endothelium-dependent relaxation and contraction in isolated blood vessels. Am J Physiol. 4:1990;226S-234S.
9. Mancini G.B.J., Henry G.C., Macaya C., O'Neill B.J., Pucillo A.L., Carere R.G., Wargovich T.J., Mudra H., Lüscher T.F., Klibaner M.I., Haber H.E., Uprichard A.C.G., Pepine C.J., Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 94:1996;258-265.
10. Husain S., Andrews N.P., Mulcahy D., Panza J.A., Quyyumi A.A. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 97:1998;716-720.
11. Dakak N., Husain S., Mulcahy D.M., Andrews N.P., Panza J.A., Waclawiw M., Schenke W., Quyyumi A.A. Contribution of nitric oxide to reactive hyperemia impact of endothelial dysfunction . Hypertension. 32:1988;9-15.
12. Lindsay D.C., Holdright D., Clarke D., Anand I.S., Poole-Wilson P.A., Collins P. Endothelial control of lower limb blood flow in chronic heart failure. Heart. 75:1996;469-476.
13. Quyyumi A.A., Dakak N., Andrews N.P., Husain S., Arora S., Gilligan D.M., Panza J.A., Cannon R.O. III. Nitric oxide activity in the human coronary circulation. J Clin Invest. 95:1995;1747-1755.
14. Barnes P.J., Karin M. Nuclear factor-kB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1997;1066-1071.
15. Benjamin N., Cockcroft J.R., Collier J.G., Dollery C.T., Ritter J., Webb D.J. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 412:1989;543-555.
16. Nakamura M., Funakoshi T., Yoshida H., Arakawa N., Suzuki T., Hiramori K. Endothelium dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers. J Cardiovasc Pharmacol. 20:1992;949-954.
17. Hirooka Y., Imaizumi T., Masaki H., Ando S., Harada S., Momohara M., Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension. 20:1992;175-180.
18. Nakamura M., Funakoshi T., Arakawa N., Yoshida H., Makita S., Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with heart failure. J Am Coll Cardiol. 24:1994;1321-1327.
19. O'Driscoll G., Green D., Rankin J., Stanton K., Taylor R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 100:1997;678-684.
20. Antony I., Lerebours G., Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold-pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation. 94:1996;3115-3122.
21. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118.
22. Creager M.A., Roddy M.-A. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension. 24:1994;499-505.
23. Kiowski W., Linder L., Nuesch R., Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension. 27:1996;371-376.
24. Wiemer G., Schölkens B.A., Becker R.H.A., Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 18:1991;558-563.
25. Busse R., Fleming I., Hecker M. Endothelium-derived bradykinin implications for angiotensin-converting enzyme-inhibitor therapy . J Cardiovasc Pharmacol. 22:(suppl. 5):1993;S31-S36.
26. Sudhir K., Chou T.M., Hutchinson S.J., Chatterjee K. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo. Circulation. 93:1996;1734-1739.
27. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 344:1994;793-795.
28. Minshall R.D., Tan F., Nakamura F., Rabito S.F., Becker R.P., Marcic B., Erdos E.G. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 81:1997;848-856.
29. Groves P., Kurz S., Just H., Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 92:1995;3424-3430.
30. Dohi Y., Hahn A.W.A., Boulanger C.M., Bühler F.R., Lüscher T.F. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat arteries. Hypertension. 19:1992;131-137.
31. Prasad A., Husain S., Mincemoyer R., Panza J.A., Cannon R.O. III, Quyyumi A.A. Coronary flow mediated vasodilation improves with angiotensin converting enzyme inhibition. (abstr) Circulation. 94:(suppl 1):1996;1-40.
32. Prasad A., Husain S., Mincemoyer R., Panza J.A., Cannon R.O. III, Quyyumi A.A. Coronary endothelial dysfunction in humans improves with angiotensin converting enzyme inhibition. (abstr) Circulation. 94:(suppl 1):1996;1-61.
33. Celermajer D.S. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 30:1997;325-333.
34. Pepine C.J. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol. 27:1996;1048-1052.